Story
Jotbody (HK) Limited, established in 2020, is a cutting-edge biotechnology company excelling in nanobody research and extracellular vesicles (EVs). Our commitment to advancing global research and development is upheld by a team of seasoned scientists and dedicated board members.
Specializing in nanobody discovery technology, we boast a rich background in customizing camelid VHH and shark vNAR. Providing a full spectrum of services in nanobody research and development, we cater to diverse needs—from antigen design and preparation to nanobody humanization and affinity maturation, along with protein expression and coupling modification services.
Our mission revolves around the development and application of nanobodies. With an international first-class team deeply immersed in biopharmaceuticals and life science tools, we leverage an advanced nanobody discovery and engineering technology platform to deliver tailored nanobody development services and high-performance research reagents to customers across over 20 countries and regions. Notably, our efforts were acknowledged by Forbes Asia in their “100 Companies to Watch in 2023” list.
Moreover, since 2014, we have been actively engaged in EV research, collaborating closely with industry and academic partners. These collaborations have enabled us to excel in EV modification for therapeutic applications, demonstrating efficacy across various disease models such as cancer, neurodegenerative disorders, cardiovascular diseases, and inflammatory conditions.
Within the realm of EVs, we offer a comprehensive suite of services tailored to meet the evolving needs of researchers worldwide. From isolation and purification to characterization, omics analysis, functionalization, and CDMO solutions, we stand as a reliable partner for researchers delving into the complexities of intercellular communication and harnessing the therapeutic benefits of EVs.
At the core of our vision lies the goal of elevating life sciences through the precision of nanobodies and the incredible potential of extracellular vesicles. We are passionate about fostering collaboration, igniting innovation, and upholding the highest standards of quality in all our endeavors, driving significant progress in the fields of nanobody research and EVs.
Strategic partnerships
We are always on the lookout for innovative solutions that can address unmet needs. If you feel that your product aligns with our vision, we would be thrilled to explore the possibility of working together.
Milestones
The 4th China (Guangdong) Chuangyi Innovation and Entrepreneurship Preliminary Competition, Silver Award
2021
The 13th Ching (Shenzhen) Innovation and Entreprenurership Competition, Shenzhen - Hong Kong-Macao University Pereliminary Competition, Winning Price
2021
Awardee of HK Tech 300 seed fund
2021
Incubatee of Shenzhen Engineering Biology Industry Innovation Center
2021
Incubatee of HKSTP Incu-Bio Programme
2021
Awardee HK Tech 300 Angel Fund
2022
Forbes Asia 100 To Watch
2023
Collaboration with Dr. Minh Le from NUS under The EVANTICA program
2024
Awardee High-Tech Enterprise of Shenzhen
2025
Awardee HKSTP Alumni Award 2026 Life & Health
2026